0001209191-20-025022.txt : 20200417
0001209191-20-025022.hdr.sgml : 20200417
20200417210906
ACCESSION NUMBER: 0001209191-20-025022
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200415
FILED AS OF DATE: 20200417
DATE AS OF CHANGE: 20200417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pande Atul
CENTRAL INDEX KEY: 0001643071
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 20801103
MAIL ADDRESS:
STREET 1: C/O AXOVANT SCIENCES, INC.
STREET 2: 1441 BROADWAY, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981333697
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 11-12 ST. JAMES'S SQUARE
STREET 2: SUITE 1, 3RD FLOOR
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 203 318 9708
MAIL ADDRESS:
STREET 1: 11 TIMES SQUARE
STREET 2: 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-15
0
0001636050
Axovant Gene Therapies Ltd.
AXGT
0001643071
Pande Atul
C/O AXOVANT GENE THERAPIES LTD.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Stock Option (Right to Buy)
3.45
2020-04-15
4
A
0
17500
0.00
A
2030-04-14
Common Shares
17500
17500
D
100% of this option will vest on April 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
/s/ Alison Haggerty, Attorney-In-Fact
2020-04-17